Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-29a
- Development stage
- Preclinical
- Lead developer
- Causeway Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intralesional
01
Overview
miR-29a (MicroRNA-29a) is a microRNA-based therapeutic candidate being investigated for its potential in treating musculoskeletal fibrotic disorders, specifically shoulder stiffness (frozen shoulder) and rotator cuff pathology. Developed by researchers at Chang Gung Memorial Hospital in Taiwan, miR-29a acts as a biologic oligonucleotide that regulates tissue homeostasis by targeting the 3'-untranslated region (3'-UTR) of Collagen type III alpha 1 (COL3A1) mRNA. By binding to this region, miR-29a suppresses the expression of COL3A1, thereby reducing the excessive formation of fibrotic extracellular matrix in myofibroblasts of the subacromial bursa and inflamed tenocytes. Preclinical and clinical research suggests that restoring miR-29a levels can alleviate tissue stiffness and maintain joint function by preventing pathological fibrosis.
- Other names
- miR-29a precursormiR29a precursormiR 29a precursormicroRNA-29a-3pmicroRNA29a-3pmicroRNA 29a-3p
02
Targets
EZH2 (Histone-lysine N-methyltransferase EZH2)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)MMP2 (Matrix metalloproteinase-2)Roundabout guidance receptor 1 (ROBO1) messenger RNAIntegrin subunit beta 1 (ITGB1) mRNALaminin subunit gamma 1 (LAMC1) mRNACOL1A1 (Collagen type I alpha 1 chain)DNMT1 (DNA (cytosine-5)-methyltransferase 1)Fibrillin-1 mRNA (FBN1 mRNA)PIK3R1 (Phosphatidylinositol 4-phosphate 3-kinase regulatory subunit alpha)Elastin messenger RNAKMT5C (Lysine methyltransferase 5C)Collagen type III alpha 1 chain mRNACollagen type I alpha 2 chain mRNAPTEN messenger RNA
Beyond the preview
Go deeper on miR-29a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-29a.